Ashton Thomas Private Wealth LLC Takes Position in Kenvue Inc. (NYSE:KVUE)

Ashton Thomas Private Wealth LLC acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 14,391 shares of the company's stock, valued at approximately $307,000.

Several other institutional investors have also recently modified their holdings of KVUE. Grove Bank & Trust increased its position in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after purchasing an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. grew its position in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares during the last quarter. Fortitude Family Office LLC grew its position in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in Kenvue during the 3rd quarter worth approximately $35,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Piper Sandler lifted their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Finally, Barclays cut their price objective on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $23.75.

Remove Ads

Kenvue Trading Down 1.7 %

KVUE opened at $23.50 on Wednesday. The stock has a market cap of $44.92 billion, a PE ratio of 44.35, a PEG ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average of $21.74 and a 200-day moving average of $22.36. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.